Meet Emerald Clinical’s Experts at CMAC 2026
Suzhou, March 18-20, 2026
Book a Meeting with Us
Come and visit us at booth G05 and meet our Head of China and Global Partnerships, Peyni Chan and the team. Our team will be on hand to share insights on navigating local regulations and optimizing your early-phase study design.
Are you looking for a CRO with integrated global capabilities and deep regional expertise?
Emerald Clinical delivers coordinated clinical development across China, EMEA, and the Americas, leveraging investigator and KOL networks to optimize execution in renal, oncology, cardiometabolic, and early-phase programs.
We provide scientific leadership and operational rigor to translate complex research into high-quality outcomes that accelerate global development.
Book a Meeting with Us
Global Site Network with Strong Early Phase Capabilities
We excel in early-phase studies, managing risk and enhancing the patient experience across our 15 sites. Our services enable rapid startup and approvals, adaptive and innovative trial designs, and robust data generation—to empower confident go/no-go decisions. Through a strong focus on safety, efficiency, and scientific rigor, we ensure seamless trial execution from concept to completion.
| “Your efficient coordination, timely documentation, and high-quality delivery enabled us to complete all pre-initiation work within three weeks, ensuring a smooth project start. Your professionalism and commitment are greatly appreciated. → China-Based Client, China Study Only |
We are the CRO of Choice for Early Phase in Australia
| Streamlined Regulatory Framework CTN scheme allows for rapid trial initiation, no need for IND | World-Class Research Infrastructure Experienced investigators and researchers, with excellent healthcare infrastructure |
| Financial Incentives R&D Tax rebate up to 43.5%, substantially reducing overall costs | International Recognition Data widely accepted by major regulatory bodies, including the EMA and FDA |
Peyni Chan
Tamara Murdock
Cory Hu
Yanqi Gao
